Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Cuts to PEPFAR Spell Detrimental HIV Outcomes in South Africa
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Despite Increases, Gender Disparities in Life Expectancy Persist Among People With HIV
As COA President, Patt Promotes Advocacy: “Each of Us Holds an Important Part of the Story”